<DOC>
	<DOCNO>NCT00938431</DOCNO>
	<brief_summary>The purpose study evaluate safety pharmacokinetics LCM syrup child age 1 month 17 year uncontrolled partial seizure add 1 3 antiepileptic drug ( AEDs ) .</brief_summary>
	<brief_title>A Multicenter , Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures</brief_title>
	<detailed_description>Six subject age 5-11 ( Cohort 1 ) initially enrol 8 mg/kg/day dose level . Upon completion study subject , pharmacokinetic safety data analyze determine target dose remain subject ( either 8 , 10 12 mg/kg/day ) . Depending select target dose , four additional age-based cohort subject enrol . LCM increase 2 mg/kg/day per week target dose maximum dose able tolerate achieve .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Subject male female 1 month 17 year age inclusive Subject 's Body Mass Index ( BMI ) within 5th 95th percentile his/her age group Subject diagnosis epilepsy partialonset seizure Subject observe uncontrolled partialonset seizure adequate course treatment least 2 antiepileptic drug ( AEDs ) ( concurrently sequentially ) Subject observe least 2 countable seizure 4week period prior Screening Subject stable dosage regimen 1 3 AEDs Subject currently participate participate within last 2 month study investigational drug experimental device Subject seizures uncountable due cluster 8week period prior study entry Subject ketogenic specialize diet Subject history primary generalize epilepsy Subject history status epilepticus within 6month period prior Screening Subject receive concomitant treatment felbamate receive previous felbamate therapy within last 6 month prior Screening Subject take currently take vigabatrin Subject take monoamine oxidase ( MAO ) inhibitor narcotic analgesic Subject lifetime history suicide attempt , suicidal ideation past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Lacosamide</keyword>
	<keyword>Vimpat</keyword>
	<keyword>Children</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Seizures</keyword>
	<keyword>Anti-epileptic</keyword>
</DOC>